Forest has well-established franchises in multiple therapeutic areas, and we are always exploring
new product opportunities that address a range of health conditions. Our principal brands include
BYSTOLIC® (nebivolol), DALIRESP® (roflumilast),
FETZIMA™ (levomilnacipran extended-release capsules),
NAMENDA® (memantine HCl),
NAMENDA XR® (memantine HCl),
SAVELLA® (milnacipran HCl),
TEFLARO® (ceftaroline fosamil) for injection,
TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder),
and VIIBRYD® (vilazodone HCl).
Forest identifies, develops, and delivers pharmaceutical products that make a difference
in people's lives. We have been extremely successful in meeting our business objectives
and expanding our franchises, but we also derive satisfaction in helping to bring
relief to people who are suffering. We credit our success to our innovation, integrity,
and commitment to developing important products.
A unique approach to product development
To provide innovative and effective medicines, we rely on a strategy that is straightforward and successful:
- License promising new products from innovative companies worldwide at virtually
every stage of development
- Conduct rigorous scientific investigation and development of drug therapies that
make a unique contribution to the field of healthcare and the lives of patients
- Execute superior marketing and sales initiatives to firmly establish our products
in the marketplace
Built on integrity
Forest proudly and actively promotes professional behavior and personal integrity
in every aspect of our business operations. We believe that the highest ethical
behavior is consistent with our ambition to deliver therapies that will favorably
impact the health and well-being of patients.
What's ahead for Forest?
At Forest, we believe in the power of potential—the potential of science, purpose,
and people. As a nimble pharmaceutical company, we are dedicated to concentrating
our energies and using our experience to bring important treatments to the marketplace.
We are proud of our success and excited by our potential. We anticipate continued,
steady growth in our product pipeline, revenues, and workforce. Learn more about
Forest by exploring our products,